Future treatment regimens may consider pretreating the T cells in TCR-T with an AMPK agonist to increase stress resistance, while utilizing tumor metabolomics to consider if AMPK is a viable target in each individual tumor setting. Here, PRKAA1 is linked to neoplasm.